American Society of Hematology (ASH) Annual Meeting

December 2, 2018

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 15, 2018

Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)

Read more

European Society for Medical Onoclogy (ESMO) Annual Meeting

October 22, 2018

Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)

Read more

European Society for Medical Onoclogy (ESMO) Annual Meeting

October 22, 2018

An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)

Read more

American Thyroid Association (ATA) Annual Meeting

October 6, 2018

Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)

Read more

Clinical Cancer Research

October 1, 2018

Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors

Read more

American Society for Bone and Mineral Research (ASBMR) Annual Meeting

September 30, 2018

BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva

Read more

IASLC World Conference on Lung Cancer

September 26, 2018

Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)

Read more

Cancer Discovery

September 26, 2018

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET…

Read more

European Hematology Association (EHA) Annual Meeting

June 15, 2018

Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1…

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 15, 2018

Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)

Read more

Cancer Discovery

April 15, 2018

Precision targeted therapy with BLU-667 for RET-driven cancers

Read more

American Society of Hematology (ASH) Annual Meeting

December 10, 2017

Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 10, 2017

Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)

Read more

Science Translational Medicine

November 1, 2017

A precision therapy against cancers driven by KIT/PDGFRA mutations

Read more

Molecular Targets and Cancer Therapeutics (AACR – NCI – EORTC)

October 29, 2017

BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers

Read more

International Liver Cancer Association (ILCA) Annual Conference

September 17, 2017

(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)

Read more

European Society for Medical Onoclogy (ESMO) Annual Meeting

September 10, 2017

Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)

Read more

World Congress on Thyroid Cancer

July 30, 2017

BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers

Read more

American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2017

Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 2, 2017

BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 2, 2017

BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)

Read more

American Society of Hematology (ASH) Annual Meeting

December 4, 2016

Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)

Read more

EORTC – NCI – AACR Molecular Targets and Cancer Therapeutics Symposium

December 1, 2016

Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in…

Read more

Molecular Targets and Cancer Therapeutics (EORTC – NCI – AACR)

November 29, 2016

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 18, 2016

The development of Potent and Selective RET inhibitors

Read more

Journal of Clinical Investigation

May 1, 2015

Targeting cancer with kinase inhibitors

Read more

Cancer Discovery

March 16, 2015

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Read more

Nature Communications

September 19, 2014

Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

Read more

Nature Communications

September 10, 2014

The landscape of kinase fusions in cancer

Read more